➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Mallinckrodt
Medtronic
Baxter

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Evacetrapib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Evacetrapib?

Evacetrapib is an investigational drug.

There have been 21 clinical trials for Evacetrapib. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemias. The leading clinical trial sponsors are Eli Lilly and Company, The Cleveland Clinic, and [disabled in preview].

There are ninety-two US patents protecting this investigational drug and seven hundred and thirty-nine international patents.

Recent Clinical Trials for Evacetrapib
TitleSponsorPhase
A Study of Different Particle Sizes of Evacetrapib in Healthy ParticipantsEli Lilly and CompanyPhase 1
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary HypercholesterolemiaEli Lilly and CompanyPhase 3
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy ParticipantsEli Lilly and CompanyPhase 1

See all Evacetrapib clinical trials

Clinical Trial Summary for Evacetrapib

Top disease conditions for Evacetrapib
Top clinical trial sponsors for Evacetrapib

See all Evacetrapib clinical trials

US Patents for Evacetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evacetrapib   Get Started Free Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Evacetrapib   Get Started Free Soluble guanylate cyclase stimulators Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Evacetrapib   Get Started Free Antidiabetic compounds Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Evacetrapib   Get Started Free [5,6]--fused bicyclic antidiabetic compounds Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evacetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Evacetrapib European Patent Office EP3174537 2034-07-29   Get Started Free
Evacetrapib World Intellectual Property Organization (WIPO) WO2016018729 2034-07-29   Get Started Free
Evacetrapib Argentina AR107154 2035-12-22   Get Started Free
Evacetrapib Australia AU2016377364 2035-12-22   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Johnson and Johnson
Baxter
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.